# Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

> **NCT03739619** · PHASE1,PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 3 (actual)

## Conditions studied

- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Classical Hodgkin Lymphoma
- Hodgkin Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Gemcitabine
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03739619
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-26
- **Primary completion:** 2023-12-22
- **Final completion:** 2025-04-30
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-08-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739619, "Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03739619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*